BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luan XR, Chen XL, Tang YX, Zhang JY, Gao X, Ke HP, Lin ZY, Zhang XN. CRISPR/Cas9-Mediated Treatment Ameliorates the Phenotype of the Epidermolytic Palmoplantar Keratoderma-like Mouse. Mol Ther Nucleic Acids 2018;12:220-8. [PMID: 30195761 DOI: 10.1016/j.omtn.2018.05.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Bchetnia M, Dionne Gagné R, Powell J, Morin C, McCuaig C, Dupérée A, Germain L, Tremblay JP, Laprise C. Allele-Specific Inactivation of an Autosomal Dominant Epidermolysis Bullosa Simplex Mutation Using CRISPR-Cas9. CRISPR J 2022. [PMID: 35862015 DOI: 10.1089/crispr.2021.0132] [Reference Citation Analysis]
2 Kocher T, Petkovic I, Bischof J, Koller U. Current developments in gene therapy for epidermolysis bullosa. Expert Opin Biol Ther 2022. [PMID: 35235467 DOI: 10.1080/14712598.2022.2049229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Morren MA, Legius E, Giuliano F, Hadj-Rabia S, Hohl D, Bodemer C. Challenges in Treating Genodermatoses: New Therapies at the Horizon. Front Pharmacol 2021;12:746664. [PMID: 35069188 DOI: 10.3389/fphar.2021.746664] [Reference Citation Analysis]
4 Koller U, Bauer JW. Gene Replacement Therapies for Genodermatoses: A Status Quo. Front Genet 2021;12:658295. [PMID: 33995490 DOI: 10.3389/fgene.2021.658295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Baker C, Hayden MS. Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease. F1000Res 2020;9:281. [PMID: 32528662 DOI: 10.12688/f1000research.23185.2] [Reference Citation Analysis]
6 Ramezankhani R, Minaei N, Haddadi M, Torabi S, Hesaraki M, Mirzaei H, Vosough M, Verfaillie CM. Gene editing technology for improving life quality: A dream coming true? Clin Genet 2021;99:67-83. [PMID: 32506418 DOI: 10.1111/cge.13794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Bodemer C, Steijlen P, Mazereeuw-Hautier J, O'Toole EA. Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature. Br J Dermatol 2021;184:393-400. [PMID: 32307694 DOI: 10.1111/bjd.19144] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Baker C, Hayden MS. Gene editing in dermatology: Harnessing CRISPR for the treatment of cutaneous disease. F1000Res 2020;9:281. [PMID: 32528662 DOI: 10.12688/f1000research.23185.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Koller U. [Ex vivo stem cell gene therapy of the skin : Ready for clinical use?]. Hautarzt 2020;71:85-90. [PMID: 31965203 DOI: 10.1007/s00105-019-04529-7] [Reference Citation Analysis]
10 March OP, Kocher T, Koller U. Context-Dependent Strategies for Enhanced Genome Editing of Genodermatoses. Cells 2020;9:E112. [PMID: 31906492 DOI: 10.3390/cells9010112] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
11 March OP, Lettner T, Klausegger A, Ablinger M, Kocher T, Hainzl S, Peking P, Lackner N, Rajan N, Hofbauer JP, Guttmann-gruber C, Bygum A, Koller U, Reichelt J. Gene Editing–Mediated Disruption of Epidermolytic Ichthyosis–Associated KRT10 Alleles Restores Filament Stability in Keratinocytes. Journal of Investigative Dermatology 2019;139:1699-1710.e6. [DOI: 10.1016/j.jid.2019.03.1146] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
12 Qasim W, Naso G, Petrova A. CRISPR/Cas9 gene editing for genodermatoses: progress and perspectives. Emerging Topics in Life Sciences 2019;3:313-26. [DOI: 10.1042/etls20180148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]